

# **SERUM CONCENTRATIONS OF CA-125 IN NORMAL AND PREECLAMPTIC PREGNANCIES**

Thesis

*Submitted for the Partial fulfillment of Master Degree  
in Obstetrics and Gynecology*

*Presented By*

**Ahmed Aziz Brekaa**

*M.B., B.Ch. Tanta University (2005)*

*Resident in Tanta General Hospital*

**Under Supervision of**

**Prof. Dr. Helmi Motawe El-Sayed**

***Professor of Obstetrics and Gynecology***

***Faculty of Medicine – Ain Shams University***

**Dr. Mohamed El-Mandooh Mohamed**

***Assistant Professor of Obstetrics and Gynecology***

***Faculty of Medicine – Ain Shams University***

**Dr. Sherif Fathi El-Mekkawi**

***Assistant Professor of Obstetrics and Gynecology***

***Faculty of Medicine – Ain Shams University***

**Faculty of Medicine**

**Ain Shams University**

**2014**

# Acknowledgement

No words can fulfill the feeling of gratitude and respect I carry for *Professor Dr. Helmi Motawe El-Sayed* for his patient guidance, enthusiastic encouragement and useful critiques of this research work.

I would like to express my great appreciation to *Dr. Mohamed El-Mandooh Mohamed* for his professional guidance, valuable support and useful and constructive recommendations on this project with a scientific personality and a kind heart.

I would like to express my deep gratitude and respect to *Dr. Sherif Fathi El-Mekkawi* for his valuable and constructive suggestions during the planning and development of this research work. His willingness to give his time so generously has been very much appreciated.

Finally, I wish to thank my family for their support and encouragement throughout my study.

*Ahmed Aziz Brekaa*

## **ABSTRACT**

**Aim:** This prospective study aims to investigate the serum concentrations of CA-125 in normal and preeclamptic pregnancies and thus to specify the value of this biochemical marker in prediction and diagnosis of preeclampsia.

**Methods:** This study reviews a total of 72 primigravid women with singleton pregnancy. These participants were categorized into two groups: control (n = 36) and preeclampsia (n = 36).

**Results:** Serum CA-125 concentrations were found to correlate positively with diastolic blood pressure ( $r = 0.345$ , P-value  $< 0.001$ ) and maternal age ( $r = 0.052$ , P-value = 0.002) but no significant correlation was found with systolic blood pressure, platelet count and gestational age at time of delivery. When the cut-off point for serum CA-125 concentration was accepted as 51.38 IU/ml, the sensitivity and specificity of this biochemical marker were, respectively, 63.9% and 97.2% for the detection of preeclamptic pregnancies. On the other hand, positive and negative predictive values for CA-125 were 95.8% and 72.9%, respectively.

**Conclusion:** This study suggests that CA-125 is a biochemical marker which reflects the underlying inflammatory process in preeclampsia.

**Keywords:** CA-125 – Preeclampsia – Pregnancy

# LIST OF CONTENTS

	<i>Page No.</i>
❖ <u>List of Figures</u> .....	i
❖ <u>List of Tables</u> .....	iii
❖ <u>List of Abbreviations</u> .....	v
❖ <u>Protocol of Thesis</u>	
❖ <u>Introduction</u> .....	1
❖ <u>Aim of Work</u> .....	3
❖ <u>Review of Literature</u> .....	4
○ Preeclampsia .....	4
• Classification and Terminology .....	4
• Incidence .....	10
• Risk Factors .....	12
• Pathophysiology .....	20
• Pathology .....	38
• Diagnosis .....	46
• Prediction .....	51
○ CA-125 .....	72
❖ <u>Patients and Methods</u> .....	82
❖ <u>Results</u> .....	89
❖ <u>Discussion</u> .....	99
❖ <u>Summary</u> .....	109
❖ <u>Conclusion</u> .....	115
❖ <u>References</u> .....	116
❖ <u>Arabic Summary</u> .....	—

## LIST OF FIGURES

<i><u>Figure No.</u></i>	<i><u>Page No.</u></i>
<b>Figure (1):</b> Difference in trophoblastic invasion and arteriolar remodeling between normal and preeclamptic pregnancies .....	22
<b>Figure (2):</b> Schematic representation of the proposed initiating events and factors in the pathophysiology of preeclampsia .....	37
<b>Figure (3):</b> Shows high resistance uterine artery Doppler at 23 weeks with increased S/D ratio and diastolic notching .....	53
<b>Figure (4):</b> PlGF and sVEGFR-1 concentrations trends during pregnancy. ....	56
<b>Figure (5):</b> The relationship between $\log_{10}$ free fetal DNA concentration and gestational age in normal pregnancy .....	58
<b>Figure (6):</b> The relationship between $\text{Log}_{10}$ free fetal DNA concentrations in pregnancies with preeclampsia and fetal growth restriction .....	59
<b>Figure (7):</b> Serum concentrations of hCG, hCG-h and their ratio during pregnancy .....	68

---

## List of Figures

---

<b>Figure (8):</b>	Comparison of maternal age (years) between preeclampsia group and normal group .....	90
<b>Figure (9):</b>	Comparison of gestational age at time of delivery (weeks) between preeclampsia group and normal group .....	91
<b>Figure (10):</b>	Comparison of systolic blood pressure (mmHg) between preeclampsia group and normal group .....	92
<b>Figure (11):</b>	Comparison of diastolic blood pressure (mmHg) between preeclampsia group and normal group .....	93
<b>Figure (12):</b>	Comparison of platelet count (x 1000/mm <sup>3</sup> ) between preeclampsia group and normal group .....	94
<b>Figure (13):</b>	Correlation between serum CA-125 level and diastolic blood pressure .....	95
<b>Figure (14):</b>	Correlation between serum CA-125 level and maternal age .....	96
<b>Figure (15):</b>	Comparison of serum CA-125 level (IU/ml) between preeclampsia group and normal group .....	97
<b>Figures (16) and (17):</b>	Receiver operating characteristics of CA-125 for preeclampsia .....	98

## LIST OF TABLES

<i><u>Table No.</u></i>	<i><u>Page No.</u></i>
<b>Table (1):</b> Conditions associated with high levels of CA-125 .....	76
<b>Table (2):</b> Comparison of maternal age (years) between preeclampsia group and normal group .....	90
<b>Table (3):</b> Comparison of gestational age at time of delivery (weeks) between preeclampsia group and normal group .....	91
<b>Table (4):</b> Comparison of systolic blood pressure (mmHg) between preeclampsia group and normal group .....	92
<b>Table (5):</b> Comparison of diastolic blood pressure (mmHg) between preeclampsia group and normal group .....	93
<b>Table (6):</b> Comparison of platelet count (x1000/microliter) between preeclampsia group and normal group .....	94
<b>Table (7):</b> Correlation between serum CA-125 level as the main parameter of study and other parameters including all cases .....	95

---

## List of Tables

---

<b>Table (8):</b>	Comparison of serum CA-125 level (IU/ml) between preeclampsia group and normal group .....	97
<b>Table (9):</b>	Receiver operating characteristics of CA-125 for preeclampsia .....	98



## LIST OF ABBREVIATIONS

<b>Aa</b>	.....Acute atherosclerosis
<b>ACOG</b>	.....American College of Obstetricians and Gynecologists
<b>Ang-1</b>	.....Angiopoietin-1
<b>Ang-2</b>	.....Angiopoietin-2
<b>Ang-II</b>	.....Angiotensin II
<b>AT1-AA</b>	.....Angiotensin II type 1 receptor autoantibody
<b>AT1-AB</b>	.....Angiotensin II type 1 receptor antibody
<b>BKCa<sup>++</sup></b>	.....Large conductance calcium-activated potassium channels
<b>BMI</b>	.....Body mass index
<b>BP</b>	.....Blood pressure
<b>CA-125</b>	.....Cancer Antigen-125
<b>CO</b>	.....Carbon monoxide
<b>CRP</b>	.....C-reactive protein
<b>CT</b>	.....Computed Tomography
<b>DIC</b>	.....Disseminated intravascular coagulation
<b>ET-1</b>	.....Endothelin-1
<b>ffDNA</b>	.....Free fetal DNA
<b>FSH</b>	.....Follicle stimulating hormone
<b>GAWS</b>	.....Genome-wide association screening
<b>GFR</b>	.....Glomerular filtration rate
<b>GWLS</b>	.....Genome-wide linkage analyses
<b>hCG</b>	.....Human chorionic gonadotropin
<b>hCG-h</b>	.....Hyperglycosylated human chorionic gonadotropin
<b>hCG-<math>\alpha</math></b>	.....Alpha subunit of human chorionic gonadotropin

---

## List of Abbreviations

---

<b>hCG-β</b>	.....Beta subunit of human chorionic gonadotropin
<b>HELLP</b>	.....Hemolysis, elevated liver enzymes, low platelet count
<b>HO-1</b>	.....Heme oxygenase-1 system
<b>IBI</b>	.....Inter-birth interval
<b>IGF</b>	.....Insulin-like growth factor
<b>IGFBP</b>	.....Insulin-like growth factor binding protein
<b>IL</b>	.....Interleukin
<b>IUFD</b>	.....Intrauterine fetal demise
<b>IUGR</b>	.....Intrauterine growth restriction
<b>kDa</b>	.....Kilodalton
<b>LH</b>	.....Luteinizing hormone
<b>MELD</b>	.....Model for End-Stage Liver Disease
<b>MRI</b>	.....Magnetic resonance image
<b>NO</b>	.....Nitric oxide
<b>OR</b>	.....Odds Ratio
<b>PAI-1</b>	.....Plasminogen activator inhibitor-type 1
<b>PAPP-A</b>	.....Pregnancy-associated plasma protein-A
<b>PCR</b>	.....Polymerase chain reaction
<b>PE</b>	.....Preeclampsia
<b>PI</b>	.....Pulsatility index
<b>PIGF</b>	.....Placental growth factor
<b>RBF</b>	.....Renal blood flow
<b>RI</b>	.....Resistive index
<b>ROS</b>	.....Reactive oxygen species
<b>RR</b>	.....Risk Ratio
<b>RUPP</b>	.....Reduced uterine perfusion pressure

---

## List of Abbreviations

---

<b>Siglec-9</b>	.....Sialic acid-binding Ig-like lectin-9
<b>sFlt-1</b>	.....Soluble fms-like tyrosine kinase-1
<b>SRD</b>	.....Serous retinal detachment
<b>sTie-2</b>	.....Soluble endothelial cell-specific tyrosine kinase receptor-2
<b>STOX-1</b>	.....Storkhead box-1
<b>sVEGFR-1</b>	...Soluble vascular endothelial growth factor receptor-1
<b>TNF</b>	.....Tumor necrosis factor
<b>TSH</b>	.....Thyroid stimulating hormone
<b>VEGF</b>	.....Vascular endothelial growth factor
<b>WHO</b>	.....World Health Organization

**SERUM CONCENTRATIONS OF  
CA-125 IN NORMAL AND  
PREECLAMPTIC PREGNANCIES**

**Protocol of Thesis**

*Submitted for the Partial fulfillment  
of Master Degree in Obstetrics and Gynecology*

**Presented By**

**Ahmed Aziz Brekaa**

*M.B., B.Ch. Tanta University (2005)  
Resident in Tanta General Hospital*

**Under Supervision of**

**Prof. Dr. Helmi Motawe El-Sayed**

*Professor of Obstetrics and Gynecology  
Faculty of Medicine - Ain Shams University*

**Dr. Mohamed El-Mandooh Mohamed**

*Assistant Professor of Obstetrics and Gynecology  
Faculty of Medicine - Ain Shams University*

**Dr. Sherif Fathi El-Mekkawi**

*Assistant Professor of Obstetrics and Gynecology  
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine  
Ain Shams University  
2013**

---

## **Introduction**

Preeclampsia complicates 3–5% of all pregnancies in the world. It is associated with hypertension and proteinuria existing after the 20<sup>th</sup> week of pregnancy. Many risk factors such as primigravida, younger age and twin pregnancy have been identified. The main consequence of placental ischemia is the generalized endothelial dysfunction, which is responsible for clinical symptoms and complications (e.g. eclampsia, placental abruption and HELLP syndrome) (*Cisse et al., 2004*).

The diagnosis of gestational hypertension is made when blood pressure reaches 140/90 mmHg or greater for the first time after mid-pregnancy in absence of proteinuria. Almost half of these women subsequently develop preeclampsia syndrome, which includes signs such as proteinuria and thrombocytopenia or symptoms such as headaches or epigastric pain. Gestational hypertension is reclassified as transient hypertension if evidence for preeclampsia does not develop, and the blood pressure returns to normal by 12 weeks postpartum (*Chesley, 1985*).

Proteinuria is the surrogate marker that defines the endothelial leak which characterizes the preeclampsia. Even so, when blood pressure increases, it's dangerous to both mother & fetus to ignore this sign because proteinuria

---

has not yet developed. It is important to know that 10% of eclamptic seizures develop before overt proteinuria is identified (*Chesley, 1985*).

Proteinuria is defined by 24 hour urinary protein excretion exceeding 300 mg, a urine protein/creatinine ratio of 0.3, or persistent 30 mg/dL (1+ dipstick) protein in random urine samples (*Lindheimer et al., 2008*).

CA-125 (Cancer Antigen-125 or Carbohydrate Antigen-125) is a large molecule mostly consisting of highly glycosylated glycoproteins. It is exposed in amnion & its derivatives of fetal coelomic epithelia (as Mullerian epithelia, peritoneum, pleura and pericardium) & in many adult tissues (as epithelium of the fallopian tubes, endometrium, endocervix, pleura and peritoneum) (*Kabawat et al. 1983*).

The normal endometrium produces CA-125 and this production can contribute significantly to the level of circulating CA-125 at the time of menstruation. During peritoneal irritation (ovarian hyperstimulation syndrome, salpingitis, ruptured ectopic pregnancy and laparotomy), peritoneally derived CA-125 significantly contributes to circulating CA-125 concentrations, giving elevated CA-125 values (*Bischof et al., 1986*).

---

In pregnant women, the CA-125 levels are increased reaching highest levels during the first trimester. The values typically decrease during the late first trimester and should remain below 35 IU/ml of serum until delivery. In some instances the maternal serum CA-125 remains within normal values (0-35 IU/ml) throughout uncomplicated pregnancies (*Kenemans et al., 1993*).